Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: Implication of epidermal growth factor receptor down-regulation and ceramide production

Prostate

Volumn 56, Issue 1, 2003, Pages 1-12

  Mimeault, Murielle ^a   Pommery, Nicole ^a   Wattez, Nicole ^b   Bailly, Christian ^b   Hénichart, Jean Pierre ^a  

^a Faculté des Sciences Pharmaceutiques et Biologiques Université de Lille   (France)

^b Institut de Recherche sur le Cancer de Lille   (France)

Author keywords

Anandamide; Apoptosis; EGF receptor; Growth inhibition; Prostatic cancer

Indexed keywords

ACYLSPHINGOSINE DEACYLASE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CERAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; ETHANOLAMINE DERIVATIVE; FUMONISIN B1; LIGAND; N OLEOYLETHANOLAMINE; RECEPTOR SUBTYPE; SPHINGOSINE ACYLTRANSFERASE; TRYPAN BLUE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER RECURRENCE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; METASTASIS; NECROSIS; PAPANICOLAOU TEST; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; STAINING;

APOPTOSIS; ARACHIDONIC ACIDS; CALCIUM CHANNEL BLOCKERS; CELL DIVISION; CERAMIDES; DOWN-REGULATION; FLOW CYTOMETRY; HUMANS; MALE; POLYUNSATURATED ALKAMIDES; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; TUMOR CELLS, CULTURED;

EID: 0038751939     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10190     Document Type: Article

References (57)

1. Lalani EN, Laniado ME, Abel PD. Molecular and cellular biology of prostate cancer. Cancer Metastasis Rev 1997;16:29-66.
2. Kim H-G, Kassis J, Souto JC, Turner T, Wells A. EGF receptor signaling in prostate morphogenesis and tumorigenesis. Histol Histopathol 1999;14:1175-1182.
3. Karp JE, Chiarodo A, Brawley O, Kelloff GJ. Prostate cancer prevention: investigational approaches and opportunities. Cancer Res 1996;56:5547-5556.
4. Untergasser G, Rumpold H, Hermamn M, Dirnhofer S, Jilg G, Berger P. Proliferative disorders of the aging human prostate: involvement of protein hormones and their receptors. Exp Gerontol 1999;34:275-287.
5. Teicher BA, Kakeji Y, Ara G, Herbst RS, Northey D. Prostate carcinoma response to cytotoxic therapy: In vivo resistance. In vivo 1997;11:453-461.
6. Aquilina JW, Lipsky JJ, Bostwick DG. Androgen deprivation as a strategy for prostate cancer chemoprevention, J Natl Cancer Inst 1997;89:689-696.
7. De Miguel P, Royuela M, Bethencourt R, Ruiz A, Fraile B, Paniagua R. Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic, and neoplastic human prostates. Cytokine 1999;11:722-727.
8. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
9. Ware JL. Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer. Cancer Metastasis Rev 1993;12:287-301.
10. Myers RB, Oelschlager D, Manne U, Coan PN, Weiss H, Grizzle WE. Androgenic regulation of growth factor and growth factor receptor expression in the CWR22 model of prostatic adenocarcinoma. Int J Cancer 1999;82:424-429.
11. Liu XH, Wiley HS, Meikle AW. Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-alpha (TGF-alpha) and epidermal growth factor (EGF)/TGF-alpha receptor. J Clin Endocrinol Metabol 1993;77:1472-1478.
12. Shuurmans AL, Bolt J, Mulder E. Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell LNCaP. Prostate 1988;12:55-63.
13. Hofer DR, Sherwood ER, Bromberg WD, Mendelsohn J, Lee C, Kozlowski JM. Autonomous growth of androgen-independent human prostatic carcinoma cells: Role of transforming growth factor alpha. Cancer Res 1991;51:2780-2785.
14. KiP1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells. Clin Cancer Res 1999;5:2171-2177.
15. Fong CJ, Sherwood ER, Mendelsohn J, Lee C, Kozlowski JM. Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor alpha. Cancer Res 1992;52:5887-5892.
16. 1 arrest in prostatic carcinoma cell line DU-145. Cancer Res 1996;56:3666-3669.
17. 1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 1996;12:1397-1403.
18. Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M, Di Marzo V. Suppression of nerve growth factor Trk receptors and prolactine receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 2000;141:118-126.
19. Di Marzo V, Melck D, De Petrocellis L, Bisogno T. Cannabimimetic fatty acid derivatives in cancer and inflammation. Chem Phys Lipids 2000;108:191-209.
20. Bisogno T, Katayama K, Melck D, Ueda N, De Petrocellis L. Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells: Implications for cell proliferation and differentiation. Eur J Biochem 1998;254:634-642.
21. De Petrocellis L, Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M, Di Marzo V. The endogenous cannabinoid anandamide inhibits human breast cancer cells proliferation. Proc Natl Acad Sci USA 1998;95:8375-8380.
22. Melck D, Rueda D, Galve-Roperh I, De Petrocellis L, Guzman M, Di Marzo V. Involvement of the cAMP/protein kinase pathway and of mitogen-activated protein-kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett 1999;463:235-240.
23. 9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Lett 1999;458:400-404.
24. 9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett 1998;436:6-10.
25. Galve-Roperh I, Sanchez C, Cortes M-L, del Pulgar TG, Izquierdo M, Guzman M. Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 2000;6:313-318.
26. Guzman M, Galve-Roperh I, Sanchez C. Ceramide: A new second messager of cannabinoid action. Trends Pharmacol Sci 2001;22:19-22.
27. Maccarrone M, Lorenzon T, Bari M, Melino G, Finazzi-Agro A. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J Biol Chem 2000;275:31938-31945.
28. Hirst SJ, Barnes PJ, Twort CH. Quantifying proliferation of cultured human and rabbit airway smooth muscle cells in response to serum and platelet derived growth factor. Am J Respir Cell Mol Biol 1992;7:574-581.
29. Papanicolaou GN. A new procedure for staining vaginal smears. Science 1942;95:438-439.
30. Kim CN, Wang X, Huang Y, Ibrado AM, Liu L, Fang G, Bhalla K. Overexpression of Bcl-XL inhibits Ara-C induced mitochondrial loss of cytochrome c and other perturbations that activate the molecular cascade of apoptosis. Cancer Res 1997;57:3115-3120.
31. Chmura SJ, Nodzenski E, Kharbanda S, Pandey P, Quintans J, Kufe DW, Weichselbaum RR. Down-regulation of ceramide production abrogates ionizing radiation-induced cytochrome c release and apoptosis. Mol Pharmacol 2000;57:792-796.
32. Wiesner DA, Kilkus JP, Gottschalh AR, Quintans J, Dawson G. Anti-immunoglobulin-induced apoptosis in WEHI 231 cells involves the slow formation of ceramide from sphingomyelin and is blocked by bcl-XL. J Biol Chem 1997;272:9868-9876.
33. 1 arrest, and anticarcinogenic effects in human prostate carcinoma DU-145 cells. Cancer Res 1998;58:1920-1929.
34. Alper O, Hacker NF, Cho-Chung YS. Protein kinase A-I alpha subunit-directed antisense inhibition of ovarian cancer cell growth: crosstalk with tyrosine kinase signaling pathway. Oncogene 1999;18:4999-5004.
35. Ciardiello F, Tortora G. Interactions between the epidermal growth factor receptor and type I protein kinase A: Biological significance and therapeutic implications. Clin Cancer Res 1998;4:821-828.
36. Nesterova M, Noguchi K, Park YG, Lee YN, Cho-Chung YS. Compensatory stabilization of RIIbeta protein, cell cycle deregulation and growth arrest in colon and prostate carcinoma cell by antisense-directed down-regulation of protein kinase A RIalpha protein. Clin Cancer Res 2000;6:3434-3441.
37. Umekita Y, Hiipakka RA, Kokontis JM, Liao S. Human prostate tumor growth in athymic mice: Inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci USA 1996;93:11802-11807.
38. Ripple MO, Henry WF, Rago RP, Wilding G. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst 1997;89:40-48.
39. Payne SG, Brindley DN, Guilbert LJ. Epidermal growth factor inhibits ceramide-induced apotosis and lowers ceramide levels in primary placental trophoblasts. J Cell Physiol 1999;180:263-270.
40. Coroneos E, Martinez M, McKenna S, Kester N. Differential regulation of sphingomyelinase and ceramidase activities by growth factors and cytokines: Implications for cellular proliferation and differentiation. J Biol Chem 1995;270:23305-23309.
41. Dorai T, Gehani N, Katz A. Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein. Mol Urol 2000;4:1-6.
42. Dorai T, Cao YC, Dorai B, Buttyan R, Katz AE. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate 2001;47:293-303.
43. Seelan RS, Qian C, Yokomizo A, Bostwick DG, Smith DI, Liu W. Human acid ceramidase is overexpressed but not mutated in prostate cancer. Genes Chromosomes Cancer 2000;29:137-146.
44. Gold R, Schmied M, Giegerich G, Breitschopf H, Hartung HP, Tokya KV, Lassmann H. Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Invest 1994;71:219-225.
45. 1 arrest and induces apoptosis in human cancer cells. Oncogene 1997;15:1903-1909.
46. Bell HS, Whittle IR, Walker M, Leaver HA, Wharton SB. The development of necrosis and apoptosis in glioma: experimental findings using spheroid culture systems. Neuropathol Appl Neurobiol 2001;27:291-304.
47. Chen CT, Burton-Wurster N, Borden C, Hueffer K, Bloom SE, Lust G. Chondrocyte necrosis and apoptosis in impact damaged articular cartilage. J Orthop Res 2001;19:703-711.
48. Toft NJ, Arends MJ. Apoptosis and necrosis in tumors. In: Martin J, editor. Apoptosis and cancer, San Diego, Calif: Basel; 1997. pp 1-24.
49. Yang GC, Papellas J, Wu HC, Waisman J. Application of Ultrafast Papanicolaou stain to body fluid cytology. Acta Cytol 2001;45:180-185.
50. Dey P, Luthra UK, George J, Zuhairy F, George SS, Haji BI. Comparaison of Thinprep and conventional preparations of fine needle aspiration cytology material. Acta Cytol 2000;44:46-50.
51. Cohen JJ. Apoptosis. Immunology Today 1993;14:126-130.
52. Gewies A, Rokhlin OW, Cohen MB. Ceramide induces cell death in the human prostatic carcinoma cell lines PC3 and DU-145 but does not seem to be involved in Fas-mediated apoptosis. Lab Invest 2000;80:671-676.
53. Engedal N, Saatcioglu F. Ceramide-induced cell death in the prostate cancer cell line LNCaP has both necrotic and apoptotic features. Prostate 2001;46:289-297.
54. Wang XZ, Beebe JR, Pwiti L, Bielawska A, Smyth MJ. Aberrant sphingolipid signaling is involved in the resistance of prostate cancer cell lines to chemotherapy. Cancer Res 1999;59:5842-5848.
55. Garzotto M, Haimovitz-Friedman A, Liao WC, White-Jones M, Huryk R, Heston WD, Cardon-Cardo C, Kolesnick R, Fuks Z. Reversal of radiation resistance in LNCaP cells by targeting apoptosis through ceramide synthase. Cancer Res 1999;59:5194-5201.
56. Kyprianou N, Martikainen P, Davis L, English HF, Isaacs JT. Programmed cell death as a new target for prostatic cancer therapy. Cancer Surv 1991;11:265-277.
57. Kyprianou N. Apoptosis: therapeutic significance in the treatment of androgen-dependent and androgen-independent prostate cancer. World J Urol 1994;12:299-303.